MGMT and neoplasm: However, Phase I trials showed that inhibitors that inactivate MGMT, improved the efficacy of BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) on tumor cells but were associated with more systemic toxicity [19], indicating MGMT expression is also vital for protecting from DNA damage in normal cells.